Assessing a Digital Platform to Improve Treatment Engagement and Outcomes for Adults in Early Psychosis Care

What this Trial Is About

Researchers are evaluating the effectiveness of the PIPPEP digital platform in improving treatment adherence and clinical outcomes for young adults aged 18 to 40 who are receiving early intervention for psychosis. This trial aims to assess whether adding the PIPPEP platform to usual care helps patients stick to their psychosocial and pharmacological treatments better. The study also looks at the platforms cost-effectiveness, its reach among patients, and effects on symptoms, medication side effects, social stigma, risk, comorbid symptoms, and social functioning. Participants are randomly assigned to one of two groups. One group receives usual care plus access to the PIPPEP platform, which provides educational content, regular self-assessment questionnaires, two-way messaging with the care team, and gamified rewards. The control group receives usual care without the platform. Questionnaires are completed at the start, six months, and twelve months, with some completed weekly. The intervention program includes multidisciplinary care with psychiatric, nursing, social work, and psychological support for up to five years. Participants will be monitored throughout the study with assessments at baseline, six months, and twelve months. These include adherence to treatment, costs, symptom impact, medication side effects, cognitive insight, substance use, anxiety and depression, social stigma, quality of life, and overall functioning. Data from questionnaires completed via the platform are securely stored in medical records. The study aims to improve engagement and prognosis by combining digital tools with personalized follow-up in early psychosis care.

Effectiveness of a Digital Platform in Engagement and Prognosis of Patients in an Early Intervention Pychosis Programme